
The Big Lesson From The Sydney Sweeney American Eagle Backlash
The campaign has been dominating headlines, but it's important to understand the wider business context. American Eagle has faced a challenging Q1 with weakening business performance due to tariffs, product misses and steep discounting. The brand has withdrawn its guidance for 2025, citing an adjusted operating loss of $68 million. In recent years, American Eagle has collaborated with the likes of Addison Rae, Coco Gauff and Yara Shahidi to win over Gen-Z and unlock new growth. The Sydney Sweeney was an attempt to further boost cultural relevance with Gen-Z. In an interview with WWD, Chief Marketing Officer Craig Brommers said, 'I think this is potentially one of the biggest gets in American Eagle history'. The campaign with Sydney Sweeney is reportedly the company's most expensive campaign to date. It was a big bet from the brand.
However, the 'great jeans' advert has received some serious backlash online. Firstly, for promoting sexual imagery while attempting to raise awareness for a domestic violence charity. Commentators were quick to criticize the campaign for appealing to the male gaze. One comment on Instagram reads: 'If your goal was to sell women's jeans to men, great job'. But the main controversy is related to the campaign messaging. On the surface, the adverts seem innocuous. The campaign tagline uses a double entendre, a form of wordplay that combines "jeans" and "genes." You can imagine the idea being blurted out during a meeting or workshop. But the campaign has been accused and criticized for promoting white supremacy and phrases coded in the language of eugenics. The video features Sweeney saying, 'Genes are passed down from parents to offspring, often determining traits like hair color, personality, and even eye color. My genes are blue.' Concluding with the slogan: 'Sydney Sweeney has great jeans'. One TikTok commentator wrote: 'It's giving 1930s Germany.'
The main critique centres on the meaning of having 'great genes'. Does it suggest the existence of less good or inferior genes? Context is important here. Sydney Sweeney is a white woman with blonde hair and blue eyes. Critics have argued that the campaign reinforces and normalizes the notion that certain genetic attributes are more desirable than others. Eugenics was a central pillar of ideology and policy in Nazi Germany. Separately from this campaign, for the first time in decades, we're witnessing eugenicist thinking from fringe to mainstream headlines. Serving as the backdrop to the American Eagle campaign. Some view the campaign as symbolic of a cultural and ideological shift back towards whiteness.Many commentators have suggested that the backlash might have been prevented if more diverse voices were included in the creative process. The problem is that diverse voices don't always translate to an equal share of influence. Challenging the consensus requires building a culture that welcomes dissent. Besides, a number of TikTok creators have pointed out that the American Eagle Executive team are all white when almost 40% of the U.S. population identifies as people of color. There also appears to be no representation of Millennials or Gen-Z on the leadership team. The very demographics the brand is hoping to connect with.
Others are celebrating the campaign for being 'anti-woke'. A return to normality, where brands and celebrities don't have to be apologetic for existing or being white. Many marketers have argued that people are reading too much into a simple brand advertisement featuring a trending celebrity to sell jeans. The internet and social media have democratized the share of voice. However, more voices create greater levels of scrutiny, resulting in countless critiques and campaign teardowns, oftentimes distant from the original creator's intentions and ambitions. It feels like marketers and brands are stuck in a lose-lose situation. Brands are bound to be criticized by one group or the other.
Where such an argument falls short is in the real world. Brands are not just logos; they are vehicles for communicating implicit and explicit meaning. Unlike broadcast media and one-way communication models, it's the audience, not the CMO, who decides how a message is received, remixed and interpreted. Advertising doesn't exist in a vacuum. Campaigns are created, transmitted and translated within the context of culture. Power has shifted from boardrooms to creators. Under such conditions, it's mission-critical to understand the cultural backdrop in which your brand is operating. Marketers need both perspective and foresight on how messages will be received in the context of the wider cultural conversation, rather than as a standalone communication.
Advertising is subliminal. Brands appeal to our subconscious emotions, intuitions and sometimes insecurities. The traditional advertising playbook rejects us as we are but embraces us if we buy the brand. Denim brands, like fragrance and luxury care brands, have historically used sexual appeal and aspiration to sell products. However, societal expectations, norms and aspirations have changed since the 20th century. A change yet to be reflected in the marketing and advertising industry. The American Eagle and Sydney Sweeney controversy will eventually blow over, but only to give way to the next consumer backlash. There is a bigger lesson to be learned from the controversy: marketers no longer control the narrative. A brand is no longer what brands tell people, but what people tell brands.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Former Reality Show Contestants Are Sharing Their Wildest And Most Shocking Experiences
A while back, I rounded up the most shocking experiences from BuzzFeed Community members who've ever appeared on or auditioned for a reality show to share their most shocking experiences. In the comments, people shared even more! Here are 16 of their top responses: Some responses are from this post and this post as well. Disclaimer: These stories have not been verified. The users are supposedly speaking from their own experiences. 1."I used to transcribe some reality TV shows, typically romance ones. The couples were genuine, and even the feelings seemed real, but the lines were fed to them and twisted their emotions to be what the production companies wanted. I was paid to transcribe everything I heard, so I'd transcribe them saying one thing when the cameras weren't rolling, and then transcribe the conversation with the production team where they were prompted to word their feelings in an often manipulated way. Then I'd transcribe them repeating the lines they'd been fed back to the rolling camera. Sometimes they'd express a degree of frustration at having to use words that didn't match their true feelings. I was never a big fan of the genre, but it put me off reality TV for life." —cakecheese 2."Chef Wanted with Anne Burrell filmed at a restaurant I worked at. That's how we got the new hire executive chef we needed. The restaurant had two swinging doors, one to go in and one to go out. They had my coworker fill a tray of drinks and intentionally spill them when someone came in the opposite way through 'the only swinging door' in the restaurant. My coworker played her part masterfully. 😂" —smokinace 3."I've tried out for American Idol and The Voice. I was a karaoke DJ for 10 years. I've been asked to sing for military awards ceremonies and private parties (nothing big), but I've been told I'm a good singer, so I should try out. I went in for The Voice. They took one look at me, gave me three seconds to sing, and said bye. They didn't give anyone a real chance unless they were already interested in you." —mizmanet 4."I saw the American Idol audition experience in person. They have casting judges before you get to TV, and they deliberately filter out good singers to film the bad ones or stupid-looking costumes for entertainment." —panda_13 5."When I auditioned for American Idol, I could hear hundreds of beautiful voices that continuously got rejected. The only people I saw picked were either dressed crazily (a guy dressed in full tinfoil while holding a toothbrush as tall as him) or people who acted wildly (a girl danced her way up to a producer like Shakira in slow motion). They did make it onto the show though, so...." —helenmelon16 6."I know a couple who broke up and went to court because he wanted the ring back, and she was keeping it. They were contacted by a court TV show asking them if they wanted to be on. I imagine they have low-level employees just scrolling through state online filings of court cases looking for anything juicy." —hans___ 7."I can confirm. I took an ex to small claims court about 10 years ago and got a letter from one of those judge shows. I didn't do it, but my mom wanted me to since it was one of the judges she used to watch." —flyerboy6 8."I worked on…we'll call it a controversial UK morning talk show, which is no longer in production. We absolutely used to seek out stories in this manner, and even worse tactics. 😬" —britneypeedonaladybug 9."This girl I went to high school with tried out for The Real World in like 2008. She was pretty, popular, and dramatic and had three pet tigers, so I don't know why they passed on her. Now she's married to a famous rapper and is an influencer with more than a million IG followers." —beaniebaby99 10."I took the test for Who Wants To Be A Millionaire. Couple of things: I didn't realize you take the test first but have to stay through at least two show tapings to get your results, so I guess that's how they get at least part of their studio audience. The other thing that struck me was how hard the test questions were versus how easy the show questions were. It was curious to me how some of the contestants even made it on the show when they were missing so many of the questions. If they could pass that test in the first place, the show shoulda been a piece of cake! 🤷🏽♀️" —sthumphrey24 11."A girl I worked with was runner-up on The Bachelor. It was before it was a launching pad for social media careers, so she kept her real job and has a reasonable online presence. She actually came off as more mellow on the show than she is in person, which is probably the best outcome you can hope for." —beaniebaby99 12."Why anyone would be on a reality TV show is beyond me. There was a couple in my friend's neighborhood who were on Extreme Makeover: Home Edition. They had four kids with disabilities, so the house was built accordingly. Afterwards, the property taxes soared, and they couldn't afford to live there. They sold it and moved elsewhere. The construction was supposedly pretty half-baked, too." —demoncopperhead 13."My friend was scouted for My Strange Addiction because she makes a living through teaching and working with taxidermy. They wanted to portray her as some sort of dead animal addict who compulsively messed with the corpses. It was not the case at all. She had and has a normal life outside of her work and is perfectly healthy." —problematik 14."Went to a taping of Whose Line Is It Anyway?. Ruined the show for me. They did multiple takes of a lot of it, with some jokes repeated, and others slightly tweaked." —mustaaaaard 15."I had a friend go on Tattoo Fixers. He was shown the designs before he actually went on the show, so he knew what he was going to get. The 'reveal' part was filmed a few weeks later after it'd healed, so he had to fake a surprised look." —doublekmama finally: "I was on Trading Spaces while I was volunteering for the Ronald McDonald House. Doug was the designer. He chose to renovate the day room as a thank you because his nephew had cancer, and his parents had stayed in one while he was in treatment. It was really sweet and turned out gorgeous." —bestunicorn88 If you've ever been on a reality show, what was your experience like? Tell us all about it in the comments or in the anonymous comments box below! Note: Some responses have been edited for length/clarity. Solve the daily Crossword
Yahoo
a few seconds ago
- Yahoo
Americans have reached their tipping point as gratuities spiral ‘out of control' — where Dave Ramsey draws a firm line
Tipping has become ubiquitous, but many Americans are burning out. Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 5 of the easiest ways you can catch up (and fast) Want an extra $1,300,000 when you retire? Dave Ramsey says this 7-step plan 'works every single time' to kill debt, get rich in America — and that 'anyone' can do it According to a recent survey by WalletHub, nearly nine in 10 believe tipping culture has 'gotten out of control,' and 83% think automatic service charges should be banned. Nearly 3 in 5 Americans think businesses are replacing employee salaries with customer tips. On a recent episode of The Ramsey Show, hosts Dave Ramsey and Jade Warshaw attempted to answer the question: When is it actually appropriate to leave a tip? When should you tip? Warshaw advised to always tip in restaurants. 'Where you're sitting down, you're placing an order, there's somebody attending to your table … tip between 18 to 20%," she asserted. "I feel like if you can't afford to leave a nice tip, you can't go." Ramsey agreed, saying staff are working for tips and often aren't paid well otherwise. For close-contact services like haircuts or nails, Warshaw recommends starting around 15%. But for quick barista service or grocery delivery? She says it depends on how great the service was, if she knows the person or if they went through a tough time to serve her, like delivering items in the rain. "For me, tipping falls in the bucket with generosity, so I overdo it," Ramsey admitted, even if the food wasn't that good. "Here's the thing: The kitchen might have screwed up, not the poor waitress." He typically wants to tip, and leaves $20 on his bed for the maid every day he stays at a hotel, but clarified, "The times that I walk up to the counter and someone spins an iPad at me and I leave a tip [are] precisely zero. I do not tip there, ever." Ramsey feels no guilt about this practice he calls a "manipulation at checkout … it's nickel-and-diming you to death.' All in all, the pair lean towards tipping and showing empathy for service workers and what they must deal with at the workplace — a sentiment not entirely reflected in the average American's view. Tipping fatigue Driven by inflation, menu price hikes and pressure to tip on basic transactions, tipping expectations are probably fueling exhaustion, resentment, and blown budgets among consumers. The same WalletHub survey found some telling information: almost 60% of Americans feel businesses are using tips to replace employee salaries, while close to 30% end up tipping less when prompted with a tip suggestion screen. What's more, 40% believe an instant employee rating system, which businesses can use to determine staff wages, should replace tipping. Read more: Nervous about the stock market in 2025? Find out how you can People are possibly feeling confused and overwhelmed by the higher number of situations for which they're expected to tip, including in quick-serve food establishments and rideshares or taxis. In fact, one-third (33%) of U.S. adults say the frequency or amount they're expected to tip has increased in the last five years, according to a Morning Consult survey. Regardless of consumer sentiment around tipping, the service industry still depends on it, since for many people, tips are essential to their income and will remain so unless their wages increase. Tips without budget stress Want to show gratitude without breaking the bank? Consider these budget-friendly ideas: Cash-only tip jar: Keep a small bill, like $1 or $2, for cash-only gratuities at coffee shops or convenience stores. Daily tracking: Add a 'tips' category to your monthly budget, so you can splurge or skip deliberately. Service-based tipping: Only tip at sit-down restaurants, delivery orders, valet and services like nail or hair — no need at counters. Modest weekly tip budget: For frequent routine services (e.g. your daily barista) to cap your spending. Evaluate, prioritize and trade off: For example, you might prefer splurging on a nice dinner out with friends each month to your convenient, weekly quick-service lunch. What to read next Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now Here are 5 simple ways to grow rich with real estate if you don't want to play landlord. And you can even start with as little as $10 Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. This article provides information only and should not be construed as advice. It is provided without warranty of any kind.
Yahoo
a few seconds ago
- Yahoo
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data